Welcome to the latest edition of our weekly EuroBiotech Report. The United Kingdom government kicked off a review it hopes will deliver a faster, cheaper way of developing drugs. Data held in health records are expected to play a bigger role as the government tries to move away from the traditional model of trialling and assessing drugs. The cost of this traditional model forced several European biotechs to consider their finances this week. Onxeo unveiled plans to raise €41.6 million ($52.2 million). Galapagos revealed it will consider listing on Nasdaq if AbbVie backs out of their rheumatoid arthritis deal. And Efranat raised $4.5 million to trial a cancer drug with a controversial history. Finally, one of the researchers trialling GlaxoSmithKline's Ebola vaccine said the study has yielded "very satisfactory" safety data so far. And more. Read the full report >>
A few things struck us while gathering this year's class of the Fierce 15, our 12th annual take on some of the most noteworthy private biotech upstarts making headway these days. First, you'll find a higher than usual accumulation of early-stage companies in the group. And it's not hard to see why. Once the IPO window opened in early 2013, we saw a whole slew of earlier winners jump through--many like bluebird and Agios winning some extraordinary returns for investors. By the end of last year we were beginning to see plenty of other newcomers make the move as well, definitely winnowing out the number of more advanced companies to select from.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no guarantee of success, particularly in this increasingly challenging market. At the same time, though, it was no great feat to find 15 women who have been doing some amazing things. Check out the special report >>
Welcome to the hall of shame, where blockbuster drug projections go to die. Here you'll find some drugs that clearly should never have wound up in Phase III to begin with, a few that were actually steered back to the clinic in a doomed attempt to mine something positive after wasting millions on clinical trials and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology. Read more >>
It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the NASDAQ Biotechnology Index (NBI), mostly driven by their participation in some of the top biotech performers this year.
POPULAR COMMENT THREADS
AbbVie is one step closer to challenging Gilead Sciences' dominance in the hepatitis C market, securing a likely European approval for its rival combo treatment as it awaits a U.S. nod.
The FDA approved Purdue Pharma's latest pain drug, a hydrocodone formulation designed to prevent abuse, potentially spelling trouble for Zogenix and its controversial Zohydro.
Novartis is well on its way to leading a new class of anti-inflammatory treatments, convincing European regulators to recommend approving its injected therapy for psoriasis and putting the company in line for transatlantic launches next year.
The SEC has suspended the trading of a few microcap companies touting unverified Ebola treatments and tests, warning investors of penny stock peddlers looking to cash in on the West African outbreak that has killed thousands.
San Diego's Neothetics, developer of a fat-busting treatment, came through on its plans to raise $65 million in an IPO, but, in keeping with a growing trend in biotech, watched its shares slide shortly after its debut.
Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $200 million to build the capacity it will need to follow through on those in-development projects.
From Our Sister Sites
Ohio-headquartered CRO Ricerca Biosciences can put off its liquidation plans, as the company has found an acquirer to keep its doors open just ahead of a self-imposed deadline.
LabCorp and CareDx have officially pulled the plug on a previously announced agreement to develop a lupus flare predictor test after completing the first phase of their collaboration.